- Home
- SQNS vs SPRO Comparison
SQNS vs SPRO Comparison
Compare SQNS & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQNS
- SPRO
- Stock Information
- Founded
- SQNS 2003
- SPRO 2013
- Country
- SQNS France
- SPRO United States
- Employees
- SQNS N/A
- SPRO N/A
- Industry
- SQNS Semiconductors
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- SQNS Technology
- SPRO Health Care
- Exchange
- SQNS Nasdaq
- SPRO Nasdaq
- Market Cap
- SQNS 46.5M
- SPRO 164.4M
- IPO Year
- SQNS 2011
- SPRO 2017
- Fundamental
- Price
- SQNS $2.05
- SPRO $2.98
- Analyst Decision
- SQNS Strong Buy
- SPRO Buy
- Analyst Count
- SQNS 1
- SPRO 4
- Target Price
- SQNS $7.50
- SPRO $5.00
- AVG Volume (30 Days)
- SQNS 5.5M
- SPRO 1.6M
- Earning Date
- SQNS 08-22-2025
- SPRO 08-04-2025
- Dividend Yield
- SQNS N/A
- SPRO N/A
- EPS Growth
- SQNS N/A
- SPRO N/A
- EPS
- SQNS 2.16
- SPRO N/A
- Revenue
- SQNS $38,858,000.00
- SPRO $44,584,000.00
- Revenue This Year
- SQNS N/A
- SPRO N/A
- Revenue Next Year
- SQNS $93.87
- SPRO N/A
- P/E Ratio
- SQNS $0.66
- SPRO N/A
- Revenue Growth
- SQNS 40.06
- SPRO N/A
- 52 Week Low
- SQNS $0.95
- SPRO $0.51
- 52 Week High
- SQNS $4.28
- SPRO $3.09
- Technical
- Relative Strength Index (RSI)
- SQNS 63.26
- SPRO 73.48
- Support Level
- SQNS $1.34
- SPRO $2.89
- Resistance Level
- SQNS $2.68
- SPRO $3.00
- Average True Range (ATR)
- SQNS 0.27
- SPRO 0.10
- MACD
- SQNS 0.05
- SPRO -0.07
- Stochastic Oscillator
- SQNS 55.28
- SPRO 63.93
About SQNS Sequans Communications S.A.
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.